Actively Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Led by Fudan University · Updated on 2026-01-21
764
Participants Needed
15
Research Sites
414 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.
CONDITIONS
Official Title
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18-70 years old
- Eastern Oncology Collaborative Group (ECOG) physical status score of 0 or 1
- Histologically confirmed triple-negative breast cancer (negative HER2, ER, and PgR) with basal-like immunosuppressed subtype
- Stage IIA to IIIC non-metastatic triple-negative breast cancer surgically treated (pT1-3N1-3M0)
- Adequate blood counts and organ function per defined laboratory tests within 28 days before treatment
- Surgical incision fully healed before starting the study
- Use of medically accepted contraception during treatment and for at least three months after last investigational drug dose for women of reproductive potential
- Ability to understand and sign informed consent and comply with study protocol
You will not qualify if you...
- Prior neoadjuvant therapy including chemotherapy, targeted therapy, or radiotherapy
- Bilateral breast cancer
- Previous other malignancies except treated basal cell carcinoma or cervical carcinoma in situ
- Metastatic (Stage 4) breast cancer
- Any lesion classified as >T4 including skin involvement or inflammatory breast cancer
- Severe organ dysfunction or insufficiency including heart, lung, liver, or kidney
- Left ventricular ejection fraction below 50%
- Severe cardio or cerebrovascular disease within 6 months before randomization
- Poorly controlled diabetes or severe hypertension
- Pregnancy, breastfeeding, or inability to use effective contraception
- Participation in other clinical trials concurrently
- Known allergy to taxane or excipients
- Severe or uncontrolled infections
- History of substance abuse or mental disorders affecting compliance
- Judged unsuitable for the study by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
3
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
4
Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Actively Recruiting
5
Sun Yat-sen University Cancer Center
Guangdong, Guangzhou, China, 510062
Actively Recruiting
6
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China, 226006
Actively Recruiting
7
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China, 225009
Actively Recruiting
8
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110002
Actively Recruiting
9
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China, 110801
Actively Recruiting
10
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
11
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China, 200233
Actively Recruiting
12
Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai Municipality, China, 201204
Actively Recruiting
13
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China, 710061
Actively Recruiting
14
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
15
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China
Actively Recruiting
Research Team
Z
Zhi-Ming Shao, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here